Regenerx Biopharmaceuticals currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, and three active strategic licensing agreements in China, Pan Asia and in the U.S. RGN-259, the company’s TB-based ophthalmic drug candidate is being developed for dry eye syndrome and for the treatment of neurotrophic keratopathy (NK).  RGN-259 has been granted orphan status by the U.S. FDA and was recently allowed by the FDA to move into phase 3 clinical trials for the treatment of patients with NK.  RGN-352 is its phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar injuries. RGN-137 is in phase 2 clinical development. For more information, visit the company’s website at www.regenerx.com.